fbpx

Columbia, Missouri, USA and Utrecht, the Netherlands

April 9th, 2020

Harry S. Truman Memorial Veterans’ Hospital’s research program is nationally recognized, in part, because of its Biomolecular Imaging Center (BIC). Using the latest imaging technology, researchers at Truman VA’s BIC conduct preclinical and translational studies to improve the lives of Veterans and all Americans through health care discovery and innovation. To further elevate current in vivo imaging capabilities, Truman VA has acquired a new, state-of-the-art multimodal imaging system, the MILabs VECTor PET/SPECT/OI/CT system*.

According to Timothy Hoffman, PhD, Director of Truman VA’s BIC, the synergistic capabilities of the fully integrated PET/SPECT/OI/CT system opens new dimensions in preclinical and translational imaging research. “The ability to image with each modality at ultra-high resolution is further enhanced by the simultaneous acquisition of dual-isotope PET/PET, multi-isotope PET/SPECT, alpha and beta radiotherapy, and three-dimensional tomographic bioluminescence and fluorescence images. We believe that such multimodal imaging advancements will help our ongoing research programs in Oncology, Cardiovascular Disease, and Traumatic Brain Injury (TBI) research so that we gain better insights into the basic mechanisms underlying what for many remains an ‘invisible’ injury.”

Dr. Frederik Beekman, CEO/CSO of MILabs and Professor at the Technical University of Delft, the Netherlands comments: “We are honored to deliver the first of our fully-loaded VECTor6 systems to Truman VA. One of the pre-eminent research institutions of the VA, which is one of the largest Federal Research Funding organizations in the US. Veterans disorders are more complex than ever before, and we are looking forward to working with the VA Biomolecular Imaging Center to ensure that its researchers can exploit the unique multimodal synergy capabilities of our VECTor platform.”

About Truman VA’s Biomolecular Imaging Center:

Truman VA’s BIC is a nationally recognized research facility within the medical center. Its mission is to facilitate discovery and innovation through state-of-the-art research. Truman VA researchers translate study findings to develop treatments that can be brought to the bedside for improved Veteran care. For more information, please visit:    https://www.columbiamo.va.gov/services/Research.asp

About MILabs B.V.

This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging either as stand-alone or fully integrated modalities on a single integrated system. For the commercialization of this preclinical imaging platform, MILabs was awarded the Commercial Innovation of the Year 2018 at the World Molecular Imaging Congress. For more information, visit:  www.milabs.com or contact MILabs at [email protected]

*Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government and shall not be used for advertising or product endorsement purposes.

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. …

Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value …

Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs …

Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V …

Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” …

Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and …

Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of …

Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by Acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →
Scroll to Top